925922-75-4

Basic information

• Product Name: 4-(trifluoromethyl)-2-hydroxy-N-methoxy-N-methylbenzamide
• Synonyms: 4-(trifluoromethyl)-2-hydroxy-N-methoxy-N-methylbenzamide
• CAS NO: 925922-75-4
• Molecular Weight: 249.19
• Mol File: 925922-75-4.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 4-(trifluoromethyl)-2-hydroxy-N-methoxy-N-methylbenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(trifluoromethyl)-2-hydroxy-N-methoxy-N-methylbenzamide(925922-75-4)
• EPA Substance Registry System: 4-(trifluoromethyl)-2-hydroxy-N-methoxy-N-methylbenzamide(925922-75-4)

Safety Data

• Hazardous Substances Data: 925922-75-4(Hazardous Substances Data)

Upstream product

• 328-90-5 4-trifluoromethylsalicylic acid 
• 1117-97-1 N,0-dimethylhydroxylamine 
• 116332-61-7 N-methoxy-N-methyl-4-trifluoromethylbenzamide 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 

Downstream Products

• 1175134-28-7 2-isopropoxy-N-methoxy-N-methyl-4-(trifluoromethyl)benzamide 

Relevant articles and documents

5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY

The invention relates to heteroaryl compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.

C?H Oxygenation Reactions Enabled by Dual Catalysis with Electrogenerated Hypervalent Iodine Species and Ruthenium Complexes

The catalytic generation of hypervalent iodine(III) reagents by anodic electrooxidation was orchestrated towards an unprecedented electrocatalytic C?H oxygenation of weakly coordinating aromatic amides and ketones. Thus, catalytic quantities of iodoarenes in concert with catalytic amounts of ruthenium(II) complexes set the stage for versatile C?H activations with ample scope and high functional group tolerance. Detailed mechanistic studies by experiment and computation substantiate the role of the iodoarene as the electrochemically relevant species towards C?H oxygenations with electricity as a sustainable oxidant and molecular hydrogen as the sole by-product. para-Selective C?H oxygenations likewise proved viable in the absence of directing groups.

PYRIDYLPHENOL COMPOUND AND USE THEREOF

The present invention provides a compound which has metastin receptor antagonist activity and is useful for preventing and treating hormone-dependent cancer, benign prostatomegaly, endometriosis, precocious puberty, uterine myoma or the like. More specifically, the present invention provides a compound, represented by the formula: or a salt thereof, a prodrug thereof, and a pharmaceutical agent containing the same; wherein Ring A represents a 5- to 8-membered homocyclic or heterocyclic group optionally having a substituent other than formula -X-R1 wherein X represents a bond or a spacer, and R1 represents optionally substituted amino or an optionally substituted nitrogen-containing heterocyclic group; Ring B represents an optionally substituted benzene ring; R2 represents an optionally substituted homocyclic or heterocyclic group; and R3 and R4 independently represent a hydrogen atom, cyano, acyl or an optionally substituted hydrocarbon group.